Combinational treatment of 5-fluorouracil and casticin induces apoptosis in mouse leukemia WEHI-3 cells in vitro.
Animals
Antineoplastic Agents
/ administration & dosage
Apoptosis
/ drug effects
Caspases
/ metabolism
Cell Line, Tumor
Cell Survival
/ drug effects
Cytochromes c
/ metabolism
Drug Synergism
Flavonoids
/ administration & dosage
Fluorouracil
/ administration & dosage
Humans
Leukemia
/ pathology
Membrane Potential, Mitochondrial
/ drug effects
Mice
Mitochondria
/ drug effects
Reactive Oxygen Species
/ metabolism
Signal Transduction
/ drug effects
5-FU
apoptosis
caspases
casticin
mitochonfria
mouse leukemia WEHI-3 cells
Journal
Environmental toxicology
ISSN: 1522-7278
Titre abrégé: Environ Toxicol
Pays: United States
ID NLM: 100885357
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
22
10
2019
revised:
09
03
2020
accepted:
20
03
2020
pubmed:
10
4
2020
medline:
9
9
2020
entrez:
10
4
2020
Statut:
ppublish
Résumé
Leukemia is one of the major diseases causing cancer-related deaths in the young population, and its cure rate is unsatisfying with side effects on patients. Fluorouracil (5-FU) is currently used as an anticancer drug for leukemia patients. Casticin, a natural polymethoxyflavone, exerts anticancer activity against many human cancer cell lines in vitro, but no other reports show 5-FU combined with casticin increased the mouse leukemia cell apoptosis in vitro. Herein, the antileukemia activity of 5-FU combined with casticin in WEHI-3 mouse leukemia cells was investigated in vitro. Treatment of two-drug combination had a higher decrease in cell viability and a higher increase in apoptotic cell death, the level of DNA condensation, and the length of comet tail than that of 5-FU or casticin treatment alone in WEHI-3 cells. In addition, the two-drug combination has a greater production rate of reactive oxygen species but a lower level of Ca
Substances chimiques
Antineoplastic Agents
0
Flavonoids
0
Reactive Oxygen Species
0
casticin
753GT729OU
Cytochromes c
9007-43-6
Caspases
EC 3.4.22.-
Fluorouracil
U3P01618RT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
911-921Subventions
Organisme : China Medical University, Taiwan
ID : CMU107-ASIA-17
Organisme : Experiments and data analysis were performed in part through the use of the Medical Research Core Facilities Center, Office of Research & Development at China medical University, Taichung, Taiwan, R.O.C.
Organisme : ORD VA
Pays : United States
Organisme : China Medical University
Organisme : ORD VA
Pays : United States
Informations de copyright
© 2020 Wiley Periodicals, Inc.
Références
Alabsi AM, Ali R, Ideris A, et al. Anti-leukemic activity of Newcastle disease virus strains AF2240 and V4-UPM in murine myelomonocytic leukemia in vivo. Leuk Res. 2012;36:634-645.
Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67:177-193.
Zand A, Imani S, Saadati M, Borna H, Ziaei R, Honari H. Effect of age, gender and blood group on blood cancer types. Trauma Mon. 2010;15:4.
Rowe JM. AML in 2016: where we are now? Best Pract Res Clin Haematol. 2016;29:315-319.
Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937-951.
Welfare MoHa 2016 Statistics of Causes of Death. http://www.mohw.gov.tw/cp-3327-33592-2.html.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7-30.
Recher C, Beyne-Rauzy O, Demur C, et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood. 2005;105:2527-2534.
De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J. 2016;6:e441.
O'Donnell MR, Tallman MS, Abboud CN, et al. Acute myeloid leukemia, version 3.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15:926-957.
Dohner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373:1136-1152.
Rai KR, Holland JF, Glidewell OJ, et al. Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood. 1981;58:1203-1212.
Kim DS, Kang KW, Lee SR, et al. Comparison of consolidation strategies in acute myeloid leukemia: high-dose cytarabine alone versus intermediate-dose cytarabine combined with anthracyclines. Ann Hematol. 2015;94:1485-1492.
Mughal TI, Schrieber A. Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase. Biol Theory. 2010;4:315-323.
Hu Y, Xin HL, Zhang QY, Zheng HC, Rahman K, Qin LP. Anti-nociceptive and anti-hyperprolactinemia activities of Fructus Viticis and its effective fractions and chemical constituents. Phytomedicine. 2007;14:668-674.
Rasul A, Zhao BJ, Liu J, et al. Molecular mechanisms of casticin action: an update on its antitumor functions. Asian Pac J Cancer Prev. 2014;15:9049-9058.
Shen JK, Du HP, Yang M, Wang YG, Jin J. Casticin induces leukemic cell death through apoptosis and mitotic catastrophe. Ann Hematol. 2009;88:743-752.
Koh DJ, Ahn HS, Chung HS, et al. Inhibitory effects of casticin on migration of eosinophil and expression of chemokines and adhesion molecules in A549 lung epithelial cells via NF-kappaB inactivation. J Ethnopharmacol. 2011;136:399-405.
Chan EWC, Wong SK, Chan HT. Casticin from Vitex species: a short review on its anticancer and anti-inflammatory properties. J Integr Med. 2018;16:147-152.
Chou GL, Peng SF, Liao CL, et al. Casticin impairs cell growth and induces cell apoptosis via cell cycle arrest in human oral cancer SCC-4 cells. Environ Toxicol. 2018;33:127-141.
Miura K, Kinouchi M, Ishida K, et al. 5-fu metabolism in cancer and orally-administrable 5-fu drugs. Cancers (Basel). 2010;2:1717-1730.
Diasio RB, Johnson MR. Dihydropyrimidine dehydrogenase: its role in 5-fluorouracil clinical toxicity and tumor resistance. Clin Cancer Res. 1999;5:2672-2673.
Wang D, Chen Y, Fang H, et al. Increase of PRPP enhances chemosensitivity of PRPS1 mutant acute lymphoblastic leukemia cells to 5-fluorouracil. J Cell Mol Med. 2018;22:6202-6212.
Schabel FM Jr, Trader MW, Laster WR Jr, Corbett TH, Griswold DP Jr. cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat Rep. 1979;63:1459-1473.
Pratesi G, Gianni L, Manzotti C, Zunino F. Sequence dependence of the antitumor and toxic effects of 5-fluorouracil and cis-diamminedichloroplatinum combination on primary colon tumors in mice. Cancer Chemother Pharmacol. 1988;21:237-240.
Kuroki M, Nakano S, Mitsugi K, et al. In vivo comparative therapeutic study of optimal administration of 5-fluorouracil and cisplatin using a newly established HST-1 human squamous-carcinoma cell line. Cancer Chemother Pharmacol. 1992;29:273-276.
Shirasaka T, Shimamoto Y, Ohshimo H, Saito H, Fukushima M. Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo. Cancer Chemother Pharmacol. 1993;32:167-172.
Scanlon KJ, Newman EM, Lu Y, Priest DG. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci U S A. 1986;83:8923-8925.
Chan SF, Chen YY, Lin JJ, et al. Triptolide induced cell death through apoptosis and autophagy in murine leukemia WEHI-3 cells in vitro and promoting immune responses in WEHI-3 generated leukemia mice in vivo. Environ Toxicol. 2017;32:550-568.
Lu CC, Yang JS, Chiang JH, et al. Novel quinazolinone MJ-29 triggers endoplasmic reticulum stress and intrinsic apoptosis in murine leukemia WEHI-3 cells and inhibits leukemic mice. PLoS One. 2012;7:e36831.
Lee MR, Lin C, Lu CC, et al. YC-1 induces G0/G1 phase arrest and mitochondria-dependent apoptosis in cisplatin-resistant human oral cancer CAR cells. Biomedicine. 2017;7:12.
Lin JJ, Wu CC, Hsu SC, et al. Alpha-phellandrene-induced DNA damage and affect DNA repair protein expression in WEHI-3 murine leukemia cells in vitro. Environ Toxicol. 2015;30:1322-1330.
Lee CF, Chiang NN, Lu YH, et al. Benzyl isothiocyanate (BITC) triggers mitochondria-mediated apoptotic machinery in human cisplatin-resistant oral cancer CAR cells. Biomedicine. 2018;8:15.
Diezi M, Garcia E, Weid N, Beck-Popovic M. No role for cerebrospinal fluid myelin basic protein levels in patients treated for childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2009;31:393-397.
Germing U, Kundgen A, Gattermann N. Risk assessment in chronic myelomonocytic leukemia (CMML). Leuk Lymphoma. 2004;45:1311-1318.
Sabattini E, Bacci F, Sagramoso C, Pileri SA. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica. 2010;102:83-87.
Padma VV. An overview of targeted cancer therapy. Biomedicine. 2015;5:19.
Qu CY, Zhou M, Chen YW, Chen MM, Shen F, Xu LM. Engineering of lipid prodrug-based, hyaluronic acid-decorated nanostructured lipid carriers platform for 5-fluorouracil and cisplatin combination gastric cancer therapy. Int J Nanomedicine. 2015;10:3911-3920.
Jang HY, Kim DH, Lee HJ, et al. Schedule-dependent synergistic effects of 5-fluorouracil and selumetinib in KRAS or BRAF mutant colon cancer models. Biochem Pharmacol. 2019;160:110-120.
Yu CS, Huang AC, Yang JS, et al. Safrole induces G0/G1 phase arrest via inhibition of cyclin E and provokes apoptosis through endoplasmic reticulum stress and mitochondrion-dependent pathways in human leukemia HL-60 cells. Anticancer Res. 2012;32:1671-1679.
Patathananone S, Thammasirirak S, Daduang J, Chung JG, Temsiripong Y, Daduang S. Bioactive compounds from crocodile (Crocodylus siamensis) white blood cells induced apoptotic cell death in hela cells. Environ Toxicol. 2016;31:986-997.
Huang AC, Cheng YD, Huang LH, et al. Casticin induces DNA damage and impairs DNA repair in human bladder cancer TSGH-8301 cells. Anticancer Res. 2019;39:1839-1847.
Su EY, Chu YL, Chueh FS, et al. Bufalin induces apoptotic cell death in human nasopharyngeal carcinoma cells through mitochondrial ROS and TRAIL pathways. Am J Chin Med. 2019;47:237-257.
Shang HS, Shih YL, Lu TJ, et al. Benzyl isothiocyanate (BITC) induces apoptosis of GBM 8401 human brain glioblastoma multiforms cells via activation of caspase-8/bid and the reactive oxygen species-dependent mitochondrial pathway. Environ Toxicol. 2016;31:1751-1760.
Shang HS, Liu JY, Lu HF, et al. Casticin induced apoptotic cell death and altered associated gene expression in human colon cancer Colo 205 cells. Environ Toxicol. 2017;32:2041-2052.
Tsai YH, Lin JJ, Ma YS, et al. Fisetin inhibits cell proliferation through the induction of G0/G1 phase arrest and Caspase-3-mediated apoptosis in mouse leukemia cells. Am J Chin Med. 2019;47:841-863.
Liu KC, Lin YJ, Hsiao YT, et al. Tetrandrine induces apoptosis in human nasopharyngeal carcinoma NPC-TW 039 cells by endoplasmic reticulum stress and Ca(2+)/Calpain pathways. Anticancer Res. 2017;37:6107-6118.
Lee CH, Shih YL, Lee MH, et al. Bufalin induces apoptosis of human osteosarcoma U-2 OS cells through endoplasmic reticulum stress, caspase- and mitochondria-dependent signaling pathways. Molecules. 2017;22:E437. https://doi.org/10.3390/molecules22030437.
Vaux DL. Apoptogenic factors released from mitochondria. Biochim Biophys Acta. 1813;2011:546-550.
Arnoult D, Gaume B, Karbowski M, Sharpe JC, Cecconi F, Youle RJ. Mitochondrial release of AIF and EndoG requires caspase activation downstream of Bax/Bak-mediated permeabilization. EMBO J. 2003;22:4385-4399.